Physician profile
Jose Cabassa
NPI 1760526164
$23,005.56
in general payments reported to CMS, 2019-2025
39 companies · $2,082 in 2025
The $2,082 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,031 · 2020: $4,176 · 2021: $1,267 · 2022: $2,935 · 2023: $2,230 · 2024: $2,284 · 2025: $2,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,580 · Education: $16.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,579.86 |
| Education | $16.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $10,609.42 | 2019-2023 | Inbrija |
| Amneal Pharmaceuticals LLC | $1,761.05 | 2019-2025 | Crexont, Rytary, Lyvispah |
| Acadia Pharmaceuticals INC | $1,481.04 | 2019-2025 | Nuplazid |
| Abbvie INC. | $1,245.59 | 2021-2025 | Duopa, Ubrelvy, Qulipta |
| Neurelis, INC. | $1,230.93 | 2021-2025 | Valtoco |
| Kyowa Kirin, INC. | $922.79 | 2019-2025 | Nourianz |
| Mdd US Operations, LLC | $727.57 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Abbott Laboratories | $518.13 | 2019-2025 | Infinity |
| Teva Pharmaceuticals USA, INC. | $484.56 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $474.82 | 2019-2025 | |
| Pfizer INC. | $409.16 | 2023-2025 | |
| Lilly USA, LLC | $407.19 | 2022-2025 | Kisunla, Amyvid |
| Lundbeck LLC | $286.74 | 2020-2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $266.77 | 2022 | |
| Ucb, INC. | $234.99 | 2019-2024 | Rystiggo, Zilbrysq |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Cabassa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.